Biontech Appoints Guido Oelkers As CEO Effective By February 1, 2027 - BNTX News | RalliesBiontech Appoints Guido Oelkers As CEO Effective By February 1, 2027
B
BNTX• Share repurchases
- Repurchases 1,693,056 ADSs in Q2 2026 at an average price of $89.50 for $151.60 million
Q2 results and vaccine approval
- Q2 revenue: EUR 105.6 million
- Q2 net income: EUR -820.8 million
- Q2 EPS: EUR -3.24
- Receives European Commission approval for new variant-adapted COVID-19 vaccine
Leadership change and guidance revision
- Appoints Guido Oelkers as CEO effective by February 1, 2027
- "Revising our full-year 2026 financial guidance in light of recently emerged external developments," said Ramón Zapata, chief financial officer at BioNTech
- Revises FY2026 guidance: revenues €1.60–1.9 billion; adjusted research and development €2–2.3 billion; adjusted SG&A €700–800 million
•
